Avacta Treats First Patient in Phase 1 Trial of Sustained-Release Peptide Drug Conjugate AVA6103
Avacta Therapeutics has announced that the first patient has been dosed in its Phase 1 FOCUS-01 clinical trial evaluating FAP-Exd (AVA6103) — a sustained-release pre|CISION® exatecan peptide drug conjugate — in patients with advanced solid tumors.
The trial represents a significant milestone for peptide drug conjugates (PDCs), a modality gaining momentum as an alternative to antibody drug conjugates (ADCs). AVA6103 targets fibroblast activation protein (FAP), which is overexpressed in the tumor microenvironment of many cancer types, while carrying a potent exatecan payload.
Why Peptide Drug Conjugates Matter
PDCs offer several theoretical advantages over their antibody-based counterparts. Peptides are smaller, enabling deeper tissue penetration into solid tumors. They are also cheaper to manufacture and can be engineered with precise pharmacokinetic properties.
The AVA6103 construct uses Avacta's pre|CISION platform, which is designed to release the cytotoxic payload specifically in the tumor microenvironment, reducing systemic toxicity — a persistent challenge in oncology drug development.
Broader Implications for the Peptide Field
This trial adds to a growing body of clinical evidence supporting peptide-based cancer therapies. Recent advances in peptide-drug conjugates as anticancer agents have highlighted the modality's potential to deliver targeted therapy with improved therapeutic windows.
The development also reflects the broader expansion of peptide applications discussed in our coverage of AI-driven peptide drug discovery, where computational approaches are accelerating the design of novel therapeutic peptides.
FAQ
q: What is a peptide drug conjugate (PDC)? a: A PDC links a targeting peptide to a cytotoxic drug molecule. The peptide guides the drug to cancer cells, while a cleavable linker releases the payload once at the target site, reducing damage to healthy tissue.
q: What is fibroblast activation protein (FAP)? a: FAP is an enzyme highly expressed in cancer-associated fibroblasts within the tumor microenvironment of many epithelial cancers. Targeting FAP allows drug delivery specifically to tumor-adjacent tissue.
q: What does the FOCUS-01 trial aim to establish? a: The Phase 1 trial will evaluate the safety, tolerability, and preliminary efficacy of AVA6103 in patients with advanced solid tumors, while determining the recommended Phase 2 dose.
q: How do PDCs compare to ADCs? a: PDCs are typically smaller than ADCs, potentially enabling better tumor penetration. They may also offer simpler manufacturing processes and more tunable pharmacokinetic profiles.